BTW: News: IGGI got patent today!
Thursday February 27 11:33 AM EDT
IGG International, Inc. Announces Key Patent on a Novel Immunotherapeutic
Agent with Anti-Cancer and Anti-Viral Activity
CAMBRIDGE, Mass., Feb. 27 /PRNewswire/ -- International Gene Group, Inc.
(Nasdaq-OTC Bulletin Board: IGGI) today announced that the U.S. Patent and
Trademark Office has issued a patent covering the Company's
immunotherapeutic agent, MMS-1, as well as the Company's methods of
preparing the compound. MMS-1 is a carbohydrate-based agent derived from
bacterial cells that has been shown in animal models to enhance immune
system activity, particularly in the treatment of cancer and
immunosuppressive viral infections. The patent, which includes composition
of matter and use, was assigned exclusively to IGG and provides broad
product protection on the MMS-1 therapeutic compound.
"The MMS-1 is potentially a novel and important carbohydrate based molecule
in immunotherapy and the fight against cancer, and infectious diseases,"
said David Platt, Ph.D., Chief Executive Officer of IGG International. "It
has long been known that some bacteria manifest strong immunostimulatory and
anti-tumor activities. The therapeutic potential of these bacteria, however,
has been limited by their associated toxicity. MMS-1 is a purified
carbohydrate based component derived from bacteria that has shown in animal
studies to inhibit metastasis and reduce primary tumors without exhibiting
the toxicity commonly associated with whole bacteria. Preclinical animal
studies have shown positive results."
Specifically, U.S. Patent No. 5,527,770 covers a glycosylated peptide
derived from cells of the specific fungal or bacterium families. The
production methods covered by the patent include the breakdown of bacterial
cells and the subsequent separation of specific components from the
bacteria.
IGG International, Inc. is a leader in the development of complex
carbohydrate compounds, derived from naturally occurring substances, for
pharmaceutical and agricultural applications. IGGI has two wholly-owned
operating subsidiaries: International Gene Group, Inc. and Agricultural
Glycosystems, Inc. Further information is available on IGG's web site:
www.iggint.com.
Any statements contained in this release that relate to future plans, events
or performance are forward-looking statements that involve risks and
uncertainties, including, but not limited to, risks of product nonapproval
or delays by the FDA, pre-clinical and clinical trial results, product
development and market acceptance risks, the results of current and future
licensing and other collaborative relationships, the results of financing
efforts, developments regarding intellectual property rights and litigation,
and other risks identified in the Company's Securities and Exchange
Commission filings. Actual results, events or performance may differ
materially. Readers are cautioned not to place undo reliance on these
forward-looking statements, which speak only as the date hereof. The Company
undertakes no obligation to publicly release the results of any revisions to
these forward- looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. SOURCE IGG International, Inc. |
